• Home
  • /Archive by category ' General '

Archive For: General

LUNES DE PATENTES

LUNES DE PATENTES

At the invitation of Prof. Pascual SEGURA, Professor at the UB Patent Center of the University of Barcelona, Bernd FABRY, CEO of IP2 Patentanwalts GmbH, gave around 80 lawyers and law students an overview of German employee invention law at the „Lunes de Patentes“ event, in particular with regard to employer obligations, inventors compensation and ... Read More
 
NEYMAR GOT HIS NAME BACK

NEYMAR GOT HIS NAME BACK

With the good name of sport stars, good money can still be earned – even if this takes place in the grey area of the legally permissible. Boris Becker can sing a song about it and now the Brazilian superstar Neymar has had to learn how quickly the right to his own name can be ... Read More
 
SWITZERLAND CREATES NEW EXTENSION FOR SPC

SWITZERLAND CREATES NEW EXTENSION FOR SPC

Supplemental Protection Certificates (SPC) can extend a patent right for a maximum of five years. A six-month additional extension is available in accordance with Regulation (EC) No 1901/2006 if the SPC relates to a medicinal product for children for which data has been submitted according to a Pediatric Investigation Plan (PIP). PIPs are required to ... Read More
 
CHINA: NEW DEVELOPMENTS FOR PHARMACEUTICAL PATENTS

CHINA: NEW DEVELOPMENTS FOR PHARMACEUTICAL PATENTS

Ticagrelor (trade name Brilinta, Brilique, and Possia) is a blockbuster drug produced by AstraZeneca with total sales of $1,079m in 2017. Ticagrelor: is a platelet aggregation inhibitor and is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. 
 
GILEAD DEFENDS THEIR SOFOSBUVIR PATENT SUCCESSFULLY

GILEAD DEFENDS THEIR SOFOSBUVIR PATENT SUCCESSFULLY

Sofusbovir is a substance from the group of nucleotide prodrugs, which has been successfully marketed by the US pharmaceutical company Gilead since 2013 as a medicament under the brand name „SOVALDI“. Sofosbuvir inhibits the RNA-dependent enzyme NS5B polymerase, which plays an important role in the replication of specific viruses. Thus, the substance is effective against ... Read More